MCL1 and pancreatic neoplasm: It is reported that Sorafenib decreased constitutive STAT3 phosphorylation (Tyr705) as well as Mcl-1 and Bcl-xL expression in a dose-dependent manner to enhance TRAIL-mediated apoptosis in pancreatic cancer cell lines.